Conray (IOTHALAMATE MEGLUMINE)
Conray (IOTHALAMATE MEGLUMINE) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Conray; Generic name: IOTHALAMATE MEGLUMINE; Manufacturer: Liebel-Flarsheim Company LLC.
| Brand name | Conray |
|---|---|
| Generic name | IOTHALAMATE MEGLUMINE |
| Manufacturer | Liebel-Flarsheim Company LLC |
| Used for | INDICATIONS AND USAGE Conray is indicated for use in excretory urography, cerebral angiography, peripheral arteriography, venography, arthrography, direct cholangiography, endoscopic retrograde cholangiopancreatography, contrast enhancement of computed tomographic brain images, cranial computerized angiotomography, intravenous digital subtraction angiography and arterial digital subtraction angiography. Conray may also be used for enhancement of computed tomographic scans performed for detection and evaluation of lesions in the liver, pancreas, kidneys, abdominal aorta, mediastinum, abdominal cavity and retroperitoneal space. Continuous or multiple scans separated by intervals of 1 to 3 seco |
| Dosage | DOSAGE AND ADMINISTRATION It is advisable that Conray be at or close to body temperature when injected. The patient should be instructed to omit the meal that precedes the examination. Appropriate premedication, which may include a barbiturate, tranquilizer or analgesic drug, may be administered prior to the examination. A preliminary film is recommended to check the position of the patient and the x-ray exposure factors. If a minor reaction occurs during administration, the injection should be |
| Warnings | WARNINGS SEVERE ADVERSE EVENTS - INADVERTENT INTRATHECAL ADMINISTRATION: Serious adverse reactions have been reported due to the inadvertent intrathecal administration of iodinated contrast media that are not indicated for intrathecal use. These serious adverse reactions include: death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. Special attention must be given to ensure that this |
| Active ingredient(s) | IOTHALAMATE MEGLUMINE |
| Route | INTRAVASCULAR |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1292abfc-496f-4df7-9a08-72072953e1f1 |